Adverse events in induction
| Event . | All patients (N = 34) . |
|---|---|
| Grade 3/4 infections | 23 patients 30 episodes MDI, n = 10 (gram negative, n = 7*; gram positive, n = 2†; candidemia, n = 1) Febrile neutropenia without MDI or CDI, n = 8 Probable fungal pneumonia, n = 11 Bacterial pneumonia, n = 1‡ |
| Pneumothorax | 1 |
| Pancreatitis | 1 |
| Grade 3/4 neuropathy | 0 |
| Cardiac arrhythmia | 1 |
| Septic cardiomyopathy | 1 |
| CNS bleed | 1 |
| GI bleed | 1 |
| Intestinal obstruction | 1 |
| Portal vein thrombosis | 1 (died during maintenance due to upper GI bleed) |
| Infusion reactions (rituximab-related) grade 3/4 | 0 |
| Tumor lysis syndrome | 3 |
| Death during induction (due to gram-negative sepsis) | 1 |
| Event . | All patients (N = 34) . |
|---|---|
| Grade 3/4 infections | 23 patients 30 episodes MDI, n = 10 (gram negative, n = 7*; gram positive, n = 2†; candidemia, n = 1) Febrile neutropenia without MDI or CDI, n = 8 Probable fungal pneumonia, n = 11 Bacterial pneumonia, n = 1‡ |
| Pneumothorax | 1 |
| Pancreatitis | 1 |
| Grade 3/4 neuropathy | 0 |
| Cardiac arrhythmia | 1 |
| Septic cardiomyopathy | 1 |
| CNS bleed | 1 |
| GI bleed | 1 |
| Intestinal obstruction | 1 |
| Portal vein thrombosis | 1 (died during maintenance due to upper GI bleed) |
| Infusion reactions (rituximab-related) grade 3/4 | 0 |
| Tumor lysis syndrome | 3 |
| Death during induction (due to gram-negative sepsis) | 1 |